# Xtant Medical Holdings, Inc.: Form 10-Q for the period ended Sep 30, 2015

- Company: [Xtant Medical Holdings, Inc.](/companies/xtnt.md) (CIK 1453593)
- Form: 10-Q
- Filed: 2015-11-16
- Accepted by EDGAR: Nov 16, 2015, 07:30 ET
- Period: 2015-09-30
- Accession: 0001144204-15-065520
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1453593/000114420415065520/v420794_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1453593/000114420415065520/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2015-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2015-07-01 to 2015-09-30 | $17.7m | us-gaap:SalesRevenueNet |
| Revenue | 9 months, 2015-01-01 to 2015-09-30 | $37.1m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2015-07-01 to 2015-09-30 | $6.0m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2015-01-01 to 2015-09-30 | $12.9m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2015-07-01 to 2015-09-30 | $11.7m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2015-01-01 to 2015-09-30 | $24.2m | us-gaap:GrossProfit |
| Research and development | 3 months, 2015-07-01 to 2015-09-30 | $794.5k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2015-01-01 to 2015-09-30 | $1.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2015-07-01 to 2015-09-30 | −$4.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2015-01-01 to 2015-09-30 | −$8.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2015-07-01 to 2015-09-30 | $2.1m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2015-01-01 to 2015-09-30 | $4.9m | us-gaap:InterestExpense |
| Net income | 3 months, 2015-07-01 to 2015-09-30 | −$6.7m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2015-01-01 to 2015-09-30 | −$13.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2015-07-01 to 2015-09-30 | −$0.64 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2015-01-01 to 2015-09-30 | −$1.70 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2015-07-01 to 2015-09-30 | −$0.64 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2015-01-01 to 2015-09-30 | −$1.70 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2015-07-01 to 2015-09-30 | 10,432,622 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2015-01-01 to 2015-09-30 | 8,100,226 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2015-01-01 to 2015-09-30 | −$9.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2015-01-01 to 2015-09-30 | $444.3k | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | at 2015-09-30 | $8.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2015-09-30 | $44.4m | us-gaap:AssetsCurrent |
| Total assets | at 2015-09-30 | $126.2m | us-gaap:Assets |
| Current liabilities | at 2015-09-30 | $16.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2015-09-30 | $129.1m | us-gaap:Liabilities |
| Long-term debt | at 2015-09-30 | $44.3m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2015-09-30 | $53.2k | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2015-09-30 | −$2.8m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1453593/000114420415065520/v420794_10q.htm

Filed Nov 16, 2015.
Source: SEC EDGAR, the filing index for accession 0001144204-15-065520. Last ingested by Listed: Oct 24, 2026, 15:08 ET. No prices; not investment advice.
